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Whilst being environmentally abundant, aluminum is not essential for life. On the contrary, aluminum is a widely recognized
neurotoxin that inhibits more than 200 biologically important functions and causes various adverse eﬀects in plants, animals,
and humans. The relationship between aluminum exposure and neurodegenerative diseases, including dialysis encephalopathy,
amyotrophic lateral sclerosis and Parkinsonism dementia in the Kii Peninsula and Guam, and Alzheimer’s disease (AD) has been
suggested. In particular, the link between aluminum and Alzheimer’s disease has been the subject of scientiﬁc debate for several
decades. However, the complex characteristics of aluminum bioavailability make it diﬃcult to evaluate its toxicity and therefore,
the relationship remains to be established. Mounting evidence has suggested that signiﬁcance of oligomerization of β-amyloid
protein and neurotoxicity in the molecular mechanism of AD pathogenesis. Aluminum may play crucial roles as a cross-linker in
β-amyloid oligomerization. Here, we review the detailed characteristics of aluminum neurotoxicity based on our own studies and
the recent literatures. Our aim is to revisit the link between aluminum and AD and to integrate aluminum and amyloid cascade
hypotheses in the context of β-amyloid oligomerization and the interactions with other metals.
1.Introduction
Aluminum (Al) is abundantly distributed in our environ-
ment, and compounds containing Al have been used in
manufacturing (e.g., clays, glasses, and alum) for centuries.
Despite its abundance, Al was ﬁrst isolated as an element
in 1827, and its use as being a silvery metal began only
after 1886. Al is a new metal in this context. Because of its
beneﬁcial characteristics such as a lightweight, nonmagnetic,
malleable, and ductile element, Al has a widespread and
important use in industrial applications and consumer
products. Al is also used in cooking utensils and in pharma-
cological agents including antacids and antiperspirants from
which the element enters the human body.
Al is not essential for life. On the contrary, Al is a well
established neurotoxin and is suspected to be linked with
various neurodegenerative diseases including Alzheimer’s
disease (AD), amyotrophic lateral sclerosis (ALS), and
Parkinsonism dementia in the Kii Peninsula and Guam [1],
and the Gulf War syndrome [2].
In particular, a possible relationship between Al and the
pathogenesis of AD has been discussed for several decades
[3–7]. AD is a severe senile type of dementia ﬁrst reported in
1906. The pathological hallmarks of AD are the deposition
of extracellular senile plaques, intracellular neuroﬁbrillary
tangles(NFTs),andtheselectivelossofsynapsesandneurons
in the hippocampal and cerebral cortical regions. The major
c o m p o n e n to fN F T si st h ep h o s p h o r y l a t e dt a up r o t e i n .
Senile plaques are largely comprised of β-amyloid protein
(AβP) [8]. The hypothesis that Al is an environmental
contributor to the pathogenesis of AD, termed the “alu-
minum hypothesis”, was proposed in the 1960s based on2 International Journal of Alzheimer’s Disease
various neurotoxicological, analytical, and epidemiological
ﬁndings [9–11]. In spite of these ﬁndings, the aluminum
hypothesis hasbeen the subjectofmuchdebate andcriticism
for several decades. During this period, great progress was
made in AD research. Particularly, numerous studies have
supported the idea termed “amyloid cascade hypothesis”,
namely that the conformational changes of AβP and its
neurotoxicity play a central role in AD pathogenesis [12,
13]. Al3+ and other metals including Zn2+,C u 2+,a n dF e 3+
inﬂuence the oligomerization and conformational changes
of AβP as cross-linkers, and, therefore, their implications are
important in this context. Furthermore, increasing evidence
suggests the implication of these metals in the pathogenesis
of AD [14–16]. Al binds to various metal-binding proteins
and inﬂuences homeostasis of other metals.
We review here the detailed characteristics of aluminum
neurotoxicity based on our own studies and the recent
literature. Our aim is to update the various adverse eﬀects
of Al and revisit the link between Al and AD based on new
ﬁndings on Al-induced conformational changes and metal-
metal interactions.
2.NeurotoxicityofAluminumUpdate
2.1. Eﬀects of Al on the Memory Disorder of Human: Historical
Overview. An association between Al poisoning and mem-
orydisorderinhumanswasﬁrstreportedin1921[17].Later,
it was shown that the intracerebral administration of Al
induced epilepsy in experimental animals [18]. As a compo-
nent of dialysis solutions or Al-containing pharmacological
compounds, Al is known to cause various dialysis-related
disorders, including osteomalacia (aluminum bone disease),
microcyticanemia,β2-microglobulin-associatedamyloidosis
[19], and dialysis encephalopathy in hemodialysis patients
[20].
The accidental contamination of Al into drinking water
occurredandmorethan20,000personswereexposedtohigh
level of Al at 1988 in Camelford (Cornwall, UK). Residents
exposed to contaminated Al exhibited various symptoms
related to cerebral impairments such as loss of concentration
and short term memory in a 10-year follow-up study [21].
Martyn et al. reported a high incidence of AD in areas
with a high level of Al in the drinking water in England
and Wales [11]. A considerable number of studies have
providedevidencetosupportanassociationbetweenADand
Al in drinking water after this initial report [22]. Frecker
reported on a Norwegian area where high Al concentrations
in drinking water were linked with high dementia mortality
[23]. Neri and Hewitt found a positive relationship between
Al in drinking water and AD risk in Canada [24]. Forbes and
McLachlan demonstrated a greater risk of AD in Canadian
areas where concentrations of Al are high and those of
ﬂuoride are low [25]. Rondeau et al. demonstrated that
high daily intake of Al was correlated with increased risk
of dementia or cognitive decline in a 15-year follow-up
French cohort study [26–28]. These studies suggest that Al
has adverse eﬀects on human memories and causes dementia
when it enters the brain.
2.2. Eﬀects of Al on the Central Nervous System In Vitro
or In Vivo. Despite it’s environmental abundance, Al is
not an essential element for living organisms, and no
enzymatic reaction requires Al. Al is reported to inﬂu-
ence more than 200 biologically important reactions and
to cause various adverse eﬀects on the mammalian cen-
tral nervous system (CNS) (Table 1). These include cru-
cial reactions for brain development such as the axonal
transport, neurotransmitter synthesis, synaptic transmis-
sion, phosphorylation or dephosphorylation of proteins,
protein degradation, gene expression, and inﬂammatory
responses.
Alexhibitsonlyoneoxidationstate,Al3+.Al 3+ hasaﬃnity
for negatively charged, oxygen-donor ligands. Inorganic and
organic phosphates, carboxylate, and deprotonated hydroxyl
groups form strong bonds with Al3+. Owing to these
chemical characteristics, Al3+ binds to the phosphate groups
of DNA and RNA, aﬀecting DNA topology and inﬂuencing
the expression of various genes essential for brain functions.
Lukiw et al. reported that nanomolar levels of Al3+ were
suﬃcient to inﬂuence neuronal gene expression [33, 35].
Al3+ also binds to the phosphate groups of nucleoside
di- and triphosphates, such as ATP and can thus inﬂuence
energy metabolism. Furthermore, Al inhibits the functions
of various protein kinases and phosphatases.
Al3+ has very low ligand-exchange rate in comparison
to other metals. For example, the ligand-exchange rate of
Mg2+ is 105 times faster than that of Al3+, and therefore,
Al3+ inhibits enzymes with Mg2+ cofactors. Al3+ also inhibits
biological processes involving rapid Ca2+ exchange: the
exchange rate for Al3+ is 108 times slower than that of Ca2+.
These properties make Al useless in enzymatic reactions and
increase its half-life in the human body. We show the typical
eﬀects of Al in Figure 1.
Al3+ has strong positive charges and a relatively small
ionic radius in comparison to other metal ions such as
Ca2+,Z n 2+,a n dN a + (Figure 2). Thus, Al3+ ﬁrmly binds to
metal-binding amino acids (histidine (His), tyrosine (Tyr),
arginine (Arg) etc.) or phosphorylated amino acids and
acts as a cross-linker; this property has made it useful as
a leather tanning agent. By binding to various proteins,
Al can cause the oligomerization of proteins, inducing
conformational changes that can inhibit their degradation
by proteases. Strong binding of Al3+ to phosphorylated
aminoacidspromotestheself-aggregationandaccumulation
of highly phosphorylated cytoskeleton proteins, including
neuroﬁlament and microtubule-associated proteins (MAPs),
and so forth [58].
Consequently, Al causes apoptotic death of neurons
and glial cells. Chronic administration of Al impairs long-
term potentiation (LTP), which is a form of synaptic
information storage well-known as a paradigm of memory
mechanisms. Al also impairs various enzymes including
those related to neurotransmitter synthesis and thus aﬀects
the neurotransmitter content. Al3+ also inhibits voltage-
gated Ca2+ channels and neurotransmitter receptors, and
impairs synaptic transmission. Finally, Al causes spatial
memory deﬁcit, inﬂuences emotional reactivity, and impairs
various brain functions related to learning and memory.International Journal of Alzheimer’s Disease 3
Table 1: Eﬀects of aluminum on the central nervous system.
References
(1) Nucleus and gene expression
Binding to DNA
Binds to histone-DNA complex and induces conformational changes of chromatin. [29]
Induces topological changes of DNA. [30, 31]
Altered gene expression
Induces decreased expression of neuroﬁlament and tubulin. [32]
Induces altered expression of genes of neuroﬁlament, APP, and neuron speciﬁc enolase. [33]
Induces decreased expression of transferrin receptor. [34]
Induces altered expression of RNA polymerase I. [35]
Induces downregulation of mitochondrial cytochrome c oxidase. [36]
Induces altered expression of calbindin-D28k. [37]
Induces decrease in the expression of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF). [38]
Induces expression of pro-inﬂammatory genes and pro-apoptotic genes. [39]
Induces elevated expression of APP. [40, 41]
Induces altered expression of oxidative stress marker genes (SOD1, glutathione reductase, etc.). [42]
Induces decreased expression of neprilysin. [43]
Induces altered expression of β-APP secretase (BACE1 and BACE2). [40, 44]
(2) Cellular functions
Energy metabolism
Inhibits the activity of hexokinase [45]
Inhibits the activity of phosphofructokinase [46]
Inhibits the activity of glucose-6-phosphate dehydrogenase [47]
Causes mitochondrial dysfunction and depletion of ATP [48, 49]
Decreases in activity and expression of TCA-cycle related enzymes (succinate dehydrogenase (SDH),
alpha-ketoglutarate dehydrogenase (KGDH), isocitrate dehydrogenase-NAD+ (IDH), fumarase (FUM), aconitase
(ACN), and cytochrome c oxidase (Cyt C Ox)).
[50]
Phosphorylation and dephosphorylation
Inhibits the activity of protein phosphatase. [51]
Increases the activity of protein kinase C and cytoskeleton proteins. [52]
Accelerates phosphorylation and accumulation of neuroﬁlament. [53]
Enhances Ca2+/Calmodulin dependent protein kinase activity. [54]
Accelerates phosphorylation of MAP 2 and neuroﬁlament. [55]
Inhibits dephosphorylation of tau. [56]
Induces nonenzymatic phosphorylation of tau. [57]
Abnormal accumulation of proteins
Causes the conformational change and the accumulation of neuroﬁlament and MAP1A, MAP1B. [58]
Accelerates the phosphorylation of tau and its accumulation. [59]
Causes the accumulation of tau protein in neuroblastoma cells or in primary cultured neurons. [60, 61]
Causes the accumulation of tau protein in experimental animals. [33, 62, 63]
Causes neuroﬁbrillary degeneration in vivo. [9]
Causes the accumulation of AβP in cultured neurons or in neuroblastoma cells. [64, 65]
Causes the accumulation of AβP in vivo. [44, 66, 67]
Neurotransmitter release
Inhibits glutamate release. [68]
Impairs synaptic transmission. [69, 70]
Inactivates glutamate dehydrogenase. [71]
Inhibits NMDA-type glutamate receptor. [72]
Inhibits choline acetyl transferase and tyrosine hydroxylase, glutamate decarboxylase. [73, 74]4 International Journal of Alzheimer’s Disease
Table 1: Continued.
References
Inﬂuences acetyl-CoA and inhibits acetylcholine release. [75]
Activates monoamine oxidase. [76, 77]
Inhibits dopamine beta-hydroxylase. [78]
Inhibits uptake of serotonin and noradrenalin in synaptosomes. [79]
Channel inhibition
Inﬂuences the activities of Na+ channels and K+ channels. [80]
Enhances the voltage-activated Na+ channels. [81]
Inhibits the voltage-gated calcium channel. [70, 82]
Inhibits the IP3-mediated Ca2+ release. [83]
Others
Inﬂuences GTP binding proteins as aluminum ﬂuoride. [84]
Inhibits GAP junction. [85]
Inhibits axonal transports. [86]
Binds to calmodulin and inhibition of calmodulin-binding enzymes. [87]
Induces inﬂammatory responses. [88]
(3) Membrane lipids
Peroxidation
Accelerates iron-induced membrane lipid peroxidation. [89]
Enhances lipid peroxidation in liposomes. [90]
Induces peroxidation of myelin lipids in vivo. [91]
Increases peroxidation products (malondialdehyde). [59]
Membrane properties
Causes the change the lipid/phospholipids proﬁles of myelin in vivo.[ 92]
Induces the change in membrane physical properties (surface potential, lipid ﬂuidity, and lipid arrangement). [91]
Induces the change of membrane ﬂuidity. [93]
(4) Higher functions
Cell death
Causes the apoptotic neuronal death. [94, 95]
Causes the apoptosis of astrocytes. [96]
Causes the death of motor neuron. [97, 98]
Behavior, learning, and memory, others
Inhibits long term potentiation (LTP). [99, 100]
Causes learning disorder or memory deﬁcit in experimental animals. [101–103]
Inﬂuences electrical activity in hippocampus and inhibits spatial learning memory deﬁcit in aging rats. [104]
Causes memory deﬁcit in AD model mice. [105, 106]
Causes encephalopathy in dialysis patients. [20]
Causes encephalopathy in patients with renal failure. [107]
Theseadverseeﬀectsmaybeinvolvedinthemechanismsthat
underlie Al-induced memory disorder.
3.LinkbetweenAl andAD
3.1. Historical Overview of Aluminum Hypothesis and Argu-
ments. A link between Al and AD is supported on many
fronts, beginning in 1965 with the ﬁnding of Klatzo et al.
that the intracerebral administration of Al to experimen-
tal animals induced neuroﬁbrillary degeneration and the
appearance of tangle-like structures that were similar to the
NFTs found in the brains of AD patients [9]. Crapper et al.
reported an increased level of Al in the brains of AD patients
[10]. In the 1970s, Al in dialysis solutions or pharmaco-
logical compounds was found to cause dementia in dialysis
patients (dialysis encephalopathy) [20]. As noted previously,
several epidemiological studies reported a high percentage
of AD cases in areas with high Al level in drinking water
[11, 19].
Despite supporting evidence, the aluminum hypothesis
of AD remains controversial and has been the subject of
much debate in the past few decades. There were at least
three arguments against the aluminum hypothesis. First,International Journal of Alzheimer’s Disease 5
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Figure 1: Eﬀects of aluminum on the central nervous system. Major biological eﬀects of Al on the central nervous system are depicted.
it has been argued that neuroﬁbrillary changes in Al-
intoxicatedanimals(Al-NFTs)arediﬀerentfromthoseinAD
patients (AD-NFTs) [108]. Arguments cite morphological
and biochemical diﬀerences such as the lack of paired helical
ﬁlamental (PHF) structures, their diﬀerent distributions in
nerve terminals, and the absence of immunoreactivity for
tau protein, which is the main component of NFTs in
AD patients. Second, there is no signiﬁcant diﬀerence in
Al levels of AD patients and age-matched controls [109].
Third, the epidemiological studies on Al in drinking water
are immature and inconclusive [110]. However, most of
these criticisms were made in the 1990s. We would like to
reinvestigate these early arguments in the context of new
ﬁndings in the study of AD.
Regarding the ﬁrst argument, more recent immunohis-
tochemical studies have indicated that depositions in the
brains of Al-intoxicated animals are stained with the anti-
tau antibody [62, 63]. The accumulation of tau protein
was reported in patients with dialysis encephalopathy [111],
and in Al-intoxicated cultured neuronal cells [60, 61]. Al
inhibits the dephosphorylation of tau [56] and enhances its
aggregation in vitro [112]. Furthermore, NFTs in some AD
patients have been shown to be composed of straight-type
ﬁlaments rather than PHF-type ﬁlaments as is observed in
Al-NFT [113]. These data indicate that attempts to discredit
the aluminum hypothesis on the basis of diﬀerences between
Al-NFTs and AD-NFTs are no longer tenable.
3.2. Accumulation of Al in AD Brain. Another argument
cites a lack of signiﬁcant diﬀerence between Al levels in
AD patients and age-matched controls. One reason for the
controversy may be Al contamination of the solutions used
in the process of tissue ﬁxation and staining. Therefore,
prior studies in ﬁxed tissues cannot be relied upon for
precise measures of Al; quantitative analysis of nonﬁxed and
freshly frozen tissues is necessary. One such study showed
that the amount of Al in whole brains of AD patients
was not signiﬁcantly diﬀerent in comparison to controls
[114]. Landsberg et al. claimed that they could not detect
Al in senile plaques or NFTs using nuclear microscopy
[115]. However, this failure could simply be due to low
detection limits of their analytical method. Bouras et al. used
highly sensitive laser microprobe mass analysis (LAMMA)
with nonﬁxed brain samples and reported an accumulation
of Al in NFT-bearing neurons of AD brains [116]. An
accumulation of Al in both senile plaques and NFTs has been
reported in renal failure patients [117]. Recently, Yumoto et
al. analyzed Al using energy-dispersive X-ray spectroscopy
combined with transmission electron microscopy (TEM-
EDX), a method which yields a high-resolution and low
detection limit. Their detailed analysis demonstrated that Al
was present in cores of senile plaques at a concentration of
35–50ppm [118].
3.3. Epidemiological Studies of AD and Al in Drinking Water.
Some epidemiological studies have failed to demonstrate the
relationship between Al and AD [119, 120]. However, there
are a number of possible explanations for this inconsistency,
particularly when considering the diﬃculty in making
side-by-side comparisons of epidemiological studies of Al
(e.g., intake estimations, eﬀect of move, changes in water-
treatment processes, etc.). Using strict neuropathological
criteria to discriminate between AD patients and controls
(including histopathological veriﬁcation), McLachlan et al.6 International Journal of Alzheimer’s Disease
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Figure 4: Aggregation of AβP by Al and other metals. (A) Immunoblotting of AβP preincubated with Al and other metals. The solutions of
AβP(1–40) were incubated at 37◦C for 24h with or without 1mM of various metals, and were analyzed by SDS-PAGE and immunoblotting
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[134]. (B) Deposition of AβP on surfaces of cultured neurons. Solutions of AβP(1–40) preincubated at 37◦Cf o r2 4h( a ) ,w i t h1m MA l C l 3
(b), or 1mM ZnCl2 (c) were applied to cultured rat cortical neurons. After 2 days of exposure, cells were washed and double immunostained
with a polyclonal antibody to AβP (green) and a monoclonal antibody to MAP2 (red), and observed by laser confocal microscope. Scale bar:
50μm, modiﬁed from [64].
found an elevated risk of histopathologically veriﬁed AD to
beassociatedwiththeconsumptionofhigherconcentrations
of Al in drinking water [121]. More detailed analysis revealed
an association between exposure to organic monomeric Al
and AD, even after adjustment for education level, family
history and presence of the apoE4 allele [122].
The amount of Al consumed in drinking water is
approximately 5% of the total daily intake. Thus, it is
possible that some factors that prevent or accelerate Al
absorption may exist in drinking water. Silicate in the water
was reported to interact with Al and prevent Al toxicity to
ﬁsh [123, 124]. Therefore, the level of silicate in drinking
water may also be important. In a French cohort study,
the relationship between Al and cognitive impairment is
suggested to be inﬂuenced by the silica concentration [29].
Cognitive impairment among women was correlated with
low concentrations of silica in drinking water [125].
In considering the above new lines of evidence about the
neurotoxicity and epidemiology of Al, it is diﬃcult to agree
with the early criticisms of the aluminum hypothesis.
3.4. Eﬀects of Al on the Oligomerization of AβP. In the
1990s when the early arguments were claimed, Al-induced
Alzheimer-like pathological changes were ﬁrst attributed
to tau proteins (NFT). However, numerous biochemical,
toxicological, cell biological, and genetic studies have sup-
ported the “amyloid cascade hypothesis”, namely, that the
accumulation of AβP and its neurotoxicity play a central role
in the pathogenesis of AD [12, 13].
AβP is a small peptide of 39–43 amino acid residues,
secreted by cleavage of the amyloid precursor protein
(APP) N-terminus by β-APP cleaving enzyme (BACE) and
intramembrane cleavage of its C-terminus by γ-secretase.
Genetic studies of early-onset cases of familial AD indicated
that APP mutations and AβP metabolism are associated with
AD [126]. Yankner et al. reported that the ﬁrst 40 amino acid
residuesofAβP(AβP(1–40))causedthedeathofculturedrat
hippocampal neurons or neurodegeneration in the brains of
experimental animals [127]. AβPi sah y d r o p h o b i cp e p t i d e
with an intrinsic tendency to self-assemble and form SDS-
stable oligomers in aqueous solution. The monomeric form8 International Journal of Alzheimer’s Disease
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of AβP has a random coiled structure. Oligomeric AβPs have
β-pleated sheet structures and form insoluble aggregates,
termed amyloid ﬁbrils. Neurotoxicity of AβP(1–40) peptides
was enhanced by the process of “aging” (aggregated under
incubation at 37◦C for several days) compared to freshly
prepared AβP(1–40) in cultured neurons [128], and were
correlatedwithits β-sheet contents [129]. Recent approaches
using size-exclusion chromatography, gel electrophoresis,
and atomic force microscopy have demonstrated that the
soluble oligomers are synaptotoxic and neurotoxic [130].
Figure 3 exhibits the oligomerization of AβP and its neuro-
toxicity.
Considering that AβP is secreted in the cerebrospinal
ﬂuid (CSF) of young individuals as well as in aged or
dementia patients [146], factors that accelerate or inhibit
oligomerization may play essential roles in the pathogenesisInternational Journal of Alzheimer’s Disease 9
Table 2: Al-induced conformational changes of various proteins.
Proteins References
Disease-related proteins
Alzheimer’s disease
AβP (1-40) [64, 131–134]
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
AβP (1-42): [135, 136]
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
AβP (25-35): [137]
GSNKGAIIGLMV
APP [138]
Tau or hyperphosphorylated tau (PHF-tau) [32, 57, 139]
Perkinson’s disease and other diseases with Lewy body
α-synuclein (NACP) [140, 141]
Type 2 diabetes mellitus
Amylin: [142]
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY
Familial British dementia
ABri: [143]
ASNCPAIRHPGNKPAVGTLICSRTVKKNIIGGN
Spinocerebellar ataxia
Ataxin 3 [144]
Dialysis-related arthropathy
β2-microglobulin [145]
of AD. Several factors such as peptide concentration, pH or
composition of solvents, and temperature can inﬂuence the
oligomerization processes [147].
Interestingly, rodent AβP exhibits less tendency to
oligomerization than human AβP in vitro [148] and the
accumulation of AβP is rarely observed in the brains of
rodents (rats or mice) as compared to primates (humans or
monkeys). As shown in Figure 3, the amino acid sequences
of human and rodent AβP are similar, but rodent AβPd i ﬀers
from primate only 3 amino acids (Arg5,T y r 10,a n dH i s 13)
from primate AβP. All 3 amino acids have the ability to
bind metals. Therefore, trace elements including Al3+ are
of particular interest as potential acceleratory factors and
may play important roles in the accumulation of AβP in the
human brain.
Table 2 summarizes the eﬀects of Al3+ on conformational
changes of AβP and other various disease-related proteins.
Exley et al. ﬁrst demonstrated by CD spectroscopy that Al
induces a conformational change in AβP(1–40) [131]. Al has
also been shown to promote the aggregation of 125I-labelled
AβP(1–40), with similar ﬁndings for Fe and Zn [132].
Bush et al. demonstrated that Zn2+ and Cu2+ caused the
oligomerization of AβP[ 149, 150]. However, role of Zn2+ in
AD is complex and enigmatic. Lovell et al. reported that zinc
has the protective eﬀects against AβP-induced neurotoxicity
[151]. We have demonstrated that Zn2+ blocks AβP-channels
formed on membranes and inhibits the neurotoxicity [152].
We have developed a system for investigating AβP
oligomerization that involves immunoblotting and pre-
cipitation. Using this system, we have demonstrated that
Al enhances the polymerization of AβP(1–40) and forms
SDS-stable oligomers in vitro [64, 133, 134]. The aggregated
AβP(1–40) is redissolved by adding deferoxamine (DFO),
an Al chelator. The oligomerization induced by Al is more
marked than that induced by other metals, including Zn2+,
Fe3+,C u 2+, and Cd2+ (Figure 4(A)). Furthermore, while Al-
aggregated AβPs bind tightly to the surface of cultured
neurons and form ﬁbrillar deposits, Zn-aggregated AβPs
are rarely observed on the surface of cultured neurons
(Figure 4(B)). These results suggest that Al-aggregated AβPs
have a strong aﬃnity for membrane surfaces as a result
of minimal degradation by proteases. Indeed, Al has been
shown to inhibit the degradation of AβP as the result of con-
formational changes [43, 153]. Furthermore, AβPc o u p l e d
with Al is more toxic than normal AβP causing membrane
disruption or perturbation of neural Ca2+ homeostasis and
mitochondrial respiration [154–156].
The chronic application of Al caused the accumulation
of AβP in cultured neurons of rat cerebral cortex [64]a n d
in neuroblastoma cells [65]. Pratic´ oe ta l . (2002) found
that orally administered Al caused a marked increase in the
amount of AβP both in its secreted and accumulated forms,
andincreaseddepositionofsenileplaquesinAD-modelmice
transfected with the human APP gene (Tg 2576) [66]. These
results are consistent with other studies demonstrating that
oralAlexposurecausestheaccumulationofAβPandimpairs
spatial learning memory in AD-model mice [67].
Exposure to Al causes the accumulation of AβPa n d
induces adverse eﬀects in humans as seen in the aftermath of
the accidental Al exposure in 1988 at Camelford [157]. The10 International Journal of Alzheimer’s Disease
neuropathological case study of a 58 year-old woman who
was exposed to Al and died 15 years later with unspeciﬁed
neurological symptoms demonstrated the rare form of
sporadic cerebral amyloid angiopathy, which is characterized
by the deposition of AβP in blood vessels and has a causative
link with AD [158]. The deposition of high amounts of Al in
the patient’s brain was also observed.
Al has also been reported to bind and cause conforma-
tional changes in other AD-related proteins, including APP
[138], tau protein [32, 57], and PHF-tau protein [139]a n d
in proteins related to other neurodegenerative diseases such
as α-synuclein (Parkinson’s disease (PD) and dementia with
Lewy bodies; DLB) [140, 141], amylin (diabetes mellitus)
[142], ABri (familial British dementia) [143], and ataxin
3 (spinocerebellar ataxia type 3) [144], β2-microglobulin
(dialysis-related arthropathy) [145]( Table 2).
3.5. Metal-Metal Interactions in the Pathogenesis of AD. The
evidence now suggests that the signiﬁcance of Al in the
pathogenesis of AD should be concerned. Other metals
usuallysharethebindingsiteofonemetalion,althoughtheir
binding constants diﬀer. Al binds to various metal-binding
proteins and inﬂuences metal homeostasis. The interactions
between Al and other metals should be considered owing
to the implications of various trace elements in the patho-
genesis of AD. Figure 5 illustrates the modiﬁed aluminum
hypothesis that accounts for the implications of Al and other
tracemetals in AD pathology from the secretion of AβPt oi t s
neurotoxicity as mentioned below.
3.5.1. Al3+ Aﬀects Iron-Homeostasis and Generates Free
Radicals. Al has similar characteristics to iron (Fe) and
binds to Fe-binding proteins such as ferritin, transferrin,
iron regulatory protein (IRP) or to iron chelators such as
DFO. The iron responsive element/iron regulatory protein
(IRE/IRP) network regulates the production of iron binding
proteins which prevent the formation of free Fe2+,w h i c h
c a u s e st o x i cf r e er a d i c a l s[ 159]. In iron-deﬁcient conditions,
IRP binds to IRE and regulates the expression of genes that
contain IREs in their mRNA, such as ferritin or transferrin.
As the concentration of free Fe2+ increases, the binding of
iron to IRP, expression of transferrin is downregulated and
that of ferritin is upregulated, and the amount of free Fe2+ is
thereby decreased. Al3+ also binds to IRP [34, 160], and thus
inﬂuences the expression of Fe-binding proteins with IREs in
their mRNA causing an elevated Fe concentration [161]. Al
also inﬂuences the uptake of iron into cultured neurons or
glial cells [34, 162]. Thus, Al3+ aﬀects iron homeostasis and
the expression of various iron-regulated proteins with IREs.
Important ﬁndings are that APP mRNA contains an IRE as
well as ferritin, and its expression is regulated by iron [163].
Indeed,AlcausedelevatedexpressionofAPPinexperimental
animals [40, 41]. Recently, Duce et al. demonstrated that
APP has ferroxidase activity, which converts Fe2+ to Fe3+
and regulates free pro-oxidant Fe2+ concentrations [164].
They also found that Zn2+ inhibits the ferroxidase activity
of APP. APP also possesses copper/zinc binding sites in
its amino-terminal domain and in the AβPd o m a i na n d
may be involved in homeostasis of these metals [165]. Al3+
stimulates Fe-induced membrane lipid peroxidation and
causes oxidative damage in vitro and in vivo, although Al3+
does not directly aﬀect peroxidation [89, 90]. There are
other important ﬁndings implicating iron homeostasis in
AD pathogenesis. Iron related genes such as transferrin C2
or hemochromatosis were revealed to be risk factors for
AD [166, 167]. Imagawa et al. (1992) reported that iron
supplementation was eﬀective for the recovery of cognitive
functions in AD patients [168].
3.5.2. Al3+ and Other Metals Enhance the Oligomerization
of AβP. An abnormal expression of APP could lead to an
increased secretion of AβP, and then enhance its accumula-
tion. Secreted AβP is usually degraded by various proteases
suchasneprilysinwithinashortperiod.Thedownregulation
of neprilysin induced by Al can cause the accumulation
AβP[ 43]. Furthermore, AβP becomes oligomerized in the
presence of trace metals such as Al3+,Z n 2+,F e 3+,a n dC u 2+,
could be resistant to proteases, and thus accumulates in the
brain.
3.5.3. Al3+ Impairs Calcium Homeostasis. AβPo l i g o m e r s
could be readily incorporated into cell membranes, resulting
in the formation of ion channels [147]. A subsequent inﬂux
of Ca2+ through these amyloid channels would lead to the
phosphorylation of tau, depletion of neurotrophic factors,
and the formation of free radicals, and so forth, with the
outcome of these eﬀects being neuronal death. Al3+ blocks
various Ca2+ channels and inﬂuences Ca2+ homeostasis.
We found that Al also inhibits the increase in Ca2+ levels
induced by brain-derived neurotrophic factor (BDNF) [94].
As described previously, Al is implicated in most of these
neurodegenerative pathways such as dephosphorylation of
tau [56], depletion of neurotrophic factor [38], formation of
free radicals [89], and induction of neuronal death.
This working hypothesis may be useful in developing an
understanding of the link between AD and trace elements
including Al, Zn, Cu, and Fe. Considering the implications
of metals in AD pathogenesis, chelation therapy for AD
treatment is of great interest [169]. Clioquinol (quinoform),
a chelator of Cu2+ or Zn2+, inhibits oligomerization of AβP
and attenuates the accumulation of amyloid in the brains of
experimental animals. Clinical trials using its analogue PBT2
are under investigation [170]. DFO, a chelator of Al and Fe,
attenuates the decline of daily living skills in AD patients
[171]. Silicates, which couple with Al and reduce its toxicity,
are also candidates for chelation therapy in AD [172].
4. Conclusion: Al andHuman Health
In this review, we have summarized the properties associated
with various aspects of Al neurotoxicity. There is growing
evidence for a link between Al and AD, and between other
metals and AD. Nevertheless, because the precise mechanism
of AD pathogenesis remains unknown, this issue is contro-
versial. However, it is widely accepted that Al is a recognized
neurotoxin, and that it could cause cognitive deﬁciencyInternational Journal of Alzheimer’s Disease 11
and dementia when it enters the brain and may have
various adverse eﬀects on CNS. In general, the absorption
of metals by the gastrointestinal tract is widely variable
and is inﬂuenced by various factors including an individual
diﬀerence, age, pH, stomach contents [173]. Recent studies
using mass spectrometry of 26Al have demonstrated that
small, but a considerable amount of Al crosses the blood
brain barrier, enters into the brain, and accumulates in a
semipermanent manner [174, 175]. Therefore, Al can cause
severe health problems in particular populations, including
infants, elderly people, and patients with impaired renal
functions, and unnecessary exposure to Al should be avoided
for such patients [176].
In 1989, a joint FAO/WHO Expert Committee on Food
Additives (JECFA) recommended a provisional tolerable
weekly intake (PTWI) of 7.0mg/kg body weight Al; however,
this was changed in 2007 to 1.0mg/kg body weight because
of potential eﬀects on the reproductive system and the devel-
oping nervous system. The characteristics of Al neurotoxity
are complex, and further research is needed especially in
relation to bioavailability, cellular eﬀects, metabolism, and
metal-metal interactions.
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